Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 4841-4847

  Hazirolan, Gulsen ^a   Canton, Emilia ^b   Sahin, Selma ^a   Arikan Akdagli, Sevtap ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; ISAVUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOOD SAMPLING; BODY FLUID; BROTH DILUTION; COLONY FORMING UNIT; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; FINE NEEDLE ASPIRATION BIOPSY; FUNGICIDAL ACTIVITY; FUNGUS CULTURE; FUNGUS GROWTH; FUNGUS ISOLATION; HUMAN; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RESPIRATORY SYSTEM; TRACHEAL ASPIRATION PROCEDURE; TRICHOSPORON ASAHII; TRICHOSPORONOSIS; TURBIDITY; URINALYSIS;

ANTIFUNGAL AGENTS; FLUCONAZOLE; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; NITRILES; PYRIDINES; PYRIMIDINES; TRIAZOLES; TRICHOSPORON;

EID: 84884238931     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00850-13     Document Type: Article

References (45)

1. Cornely OA. 2008. Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. Infection 36:296-313.
2. Taj-Aldeen SJ, Al-Ansari N, El Shafei S, Meis JF, Curfs-Breuker I, Theelen B, Boekhout T. 2009. Molecular identification and susceptibility of Trichosporon species isolated from clinical specimens in Qatar: isolation of Trichosporon dohaense Taj-Aldeen, Meis & Boekhout sp. nov. J. Clin. Microbiol. 47:1791-1799.
3. Colombo AL, Padovan AC, Chaves GM. 2011. Current knowledge of Trichosporon spp. and trichosporonosis. Clin. Microbiol. Rev. 24:682-700.
4. Mekha N, Sugita T, Ikeda R, Nishikawa A, Autthateinchai R, Poonwan N, Sawanpanyalert P. 2010. Genotyping and antifungal drug susceptibility of the pathogenic yeast Trichosporon asahii isolated from Thai patients. Mycopathologia 169:67-70.
5. Kalkanci A, Sugita T, Arikan S, Yucesoy M, Ener B, Otag F, Kiraz N, Kustimur S, Sancak B, Evci C, Emektas G. 2010. Molecular identification, genotyping, and drug susceptibility of the basidiomycetous yeast pathogen Trichosporon isolated from Turkish patients. Med. Mycol. 48: 141-146.
6. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. 2002. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob. Agents Chemother. 46:1144-1146.
7. Li H, Lu Q, Wan Z, Zhang J. 2010. In vitro combined activity of amphotericin B, caspofungin, and voriconazole against clinical isolates of Trichosporon asahii. Int. J. Antimicrob. Agents 35:550-552.
8. Thomas C, Chagas-Neto Guilherme Chaves M, Arnaldo Colombo L. 2008. Update on the genus Trichosporon. Mycopathologia 166:121-132.
9. Gueho E, Smith MT, de Hoog GS, Billon-Grand G, Christen R, Batenburg-van der Vegte WH. 1992. Contributions to a revision of the genus Trichosporon. Antonie Van Leeuwenhoeck 61:289-316.
10. Sugita T, Nishikawa A, Shinoda T. 1994. Reclassification of Trichosporon cutaneum by DNA relatedness by using the spectrophotometric method and chemiluminometric method. J. Gen. Appl. Microbiol. 40:397-408.
11. Sugita T, Nishikawa A, Shinoda T, Kume H. 1995. Taxonomic position of deep-seated, mucosa-associated, and superficial isolates of Trichosporon cutaneum from trichosporonosis patients. J. Clin. Microbiol. 33:1368-1370.
12. Li HM, Du HT, Liu W, Wan Z, Li RY. 2005. Microbiological characteristics of medically important Trichosporon species. Mycopathologia 160:217-225.
13. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. 2004. Infections due to emerging and uncommon medically important fungal pathogens. Clin. Microbiol. Infect. 10:48-66.
14. Girmenia C, Pagano L, Martino B, D'Antonio D, Fanci R, Specchia G, Melillo L, Buelli M, Pizzarelli G, Venditti M, Martino P, Infection Program GIMEMA. 2005. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J. Clin. Microbiol. 43:1818-1828.
15. Walsh TJ, Melcher GP, Rinaldi MG, Lecciones J, McGough DA, Kelly P, Lee J, Callender D, Rubin M, Pizzo PA. 1990. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J. Clin. Microbiol. 28: 1616-1622.
16. Denning DW. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151.
17. Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichner L, Cortes J, O'brien S, Verstovsek S, Faderl S, Zhou X, Raad II, Bekele BN, Leitz GJ, Lopez-Roman I, Estey EH. 2006. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob. Agents Chemother. 50:143-147.
18. Arikan S, Hasçelik G. 2002. Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates. Diagn. Microbiol. Infect. Dis. 43:107-111.
19. Larone DH. 2011. Yeast and yeast-like organisms, p 151-152. In Medically important fungi: a guide to identification, 5th ed. ASM Press, Washington, DC.
20. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, approved standard. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
21. Cantón E, Pemán J, Viudes A, Quindós G, Gobernado M, Espinel-Ingroff A. 2003. Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn. Microbiol. Infect. Dis. 45:203-206.
22. Klepser ME, Ernst EJ, Lewis RE, Ernst ME, Pfaller MA. 1998. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob. Agents Chemother. 42:1207-1212.
23. Klepser ME, Wolfe EJ, Jones RN, Nightingale CH, Pfaller MA. 1997. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother. 41:1392-1395.
24. Cantón E, Pemán J, Gobernado M, Viudes A, Espinel-Ingroff A. 2004. Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob. Agents Chemother. 48:2477-2482.
25. Cantón E, Pemán J, Gobernado M, Viudes A, Espinel-Ingroff A. 2005. Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods. Antimicrob. Agents Chemother. 49:1593-1596.
26. Jiang J. 2007. Linear and generalized linear mixed models, p 4-28. In Linear, generalized linear mixed models and their applications. Springer, Dordrecht, Netherlands.
27. Zaragoza O, Mesa-Arango AC, Gómez-López A, Bernal-Martínez L, Rodríguez-Tudela JL, Cuenca-Estrella M. 2011. Process analysis of variables for standardization of antifungal susceptibility testing of nonfermentative yeasts. Antimicrob. Agents Chemother. 55:1563-1570.
28. Rodriguez-Tudela JL, Diaz-Guerra TM, Mellado E, Cano V, Tapia C, Perkins A, Gomez-Lopez A, Rodero L, Cuenca-Estrella M. 2005. Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob. Agents Chemother. 49:4026-4034.
29. Thompson GR, III, Wiederhold NP, Sutton DA, Fothergill A, Patterson TF. 2009. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces, and Pichia species. J. Antimicrob. Chemother. 64:79-83.
30. Arikan S, Sancak B, Bolat S, Hascelik G. 2005. Comparative in vitro activity of posaconazole (POS), voriconazole (VOR), itraconazole (ITR) and fluconazole (FLU) against Trichosporon asahii, abstr M-1634. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
31. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Bijie H, Dzierzanowska D, Klimko NN, Letscher-Bru V, Lisalova M, Muehlethaler K, Rennison C, Zaidi M, Global Antifungal Surveillance Group. 2009. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 47:117-123.
32. Metin DY, Hilmioglu-Polat S, Hakim F, Inci R, Tumbay E. 2005. Evaluation of the microdilution, Etest, and disk diffusion methods for antifungal susceptibility testing of clinical strains of Trichosporon spp. J. Chemother. 17:404-408.
33. Chagas-Neto TC, Chaves GM, Melo AS, Colombo AL. 2009. Bloodstream infections due to Trichosporon spp.: species distribution, Trichosporon asahii genotypes determined on the basis of ribosomal DNA intergenic spacer 1 sequencing and antifungal susceptibility testing. J. Clin. Microbiol. 47:1074-1081.
34. Guo LN, Xiao M, Kong F, Chen SC, Wang H, Sorrell TC, Jiang W, Dou HT, Li RY, Xu YC. 2011. Three-locus identification, genotyping, and antifungal susceptibilities of medically important Trichosporon species from China. J. Clin. Microbiol. 49:3805-3811.
35. Xia Z, Yang R, Wang W, Cong L. 2012. Genotyping and antifungal drug susceptibility of Trichosporon asahii isolated from Chinese patients. Mycopathologia 173:127-133.
36. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL, Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
37. Sabo JA, Abdel-Rahman SM. 2000. Voriconazole: a new triazole antifungal. Ann. Pharmacother. 34:1032-1043.
38. Pemán J, Salavert M, Cantón E, Jarque I, Romá E, Zaragoza R, Viudes A, Gobernado M. 2006. Voriconazole in the management of nosocomial invasive fungal infections. Ther. Clin. Risk Manag. 2:129-158.
39. Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spickerman J, Weidekamm E, Brown T, Roehrle M. 2006. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob. Agents Chemother. 50:286-293.
40. Conte JE, Jr, Golden JA, Krishna G, McIver M, Little E, Zurlinden E. 2009. Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Antimicrob. Agents Chemother. 53:703-707.
41. Roling EE, Klepser ME, Wasson A, Lewis RE, Ernst EJ, Pfaller MA. 2002. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Cryptococcus neoformans via time-kill methods. Diagn. Microbiol. Infect. Dis. 43:13-17.
42. Oz Y, Dag I, Kiraz N. 2012. Broth microdilution and time-kill testing of caspofungin, voriconazole, amphotericin B, and their combinations against clinical isolates of Candida krusei. Mycopathologia 173:27-34.
43. Cantón E, Pemán J, Valentín A, Bosch M, Espinel-Ingroff A, Gobernado M. 2008. Comparison of posaconazole and voriconazole in vitro killing against Candida krusei. Diagn. Microbiol. Infect. Dis. 62:177-181.
44. Di Bonaventura G, Spedicato I, Picciani C, D'Antonio D, Piccolomini R. 2004. In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies. Antimicrob. Agents Chemother. 48:4453-4456.
45. Sóczó G, Kardos G, McNicholas PM, Balogh E, Gergely L, Varga I, Kelentey B, Majoros L. 2007. Correlation of posaconazole minimum fungicidal concentration and time kill test against nine Candida species. J. Antimicrob. Chemother. 60:1004-1009.